Cytovation Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $6M

  • Investors
  • 3

Cytovation General Information

Description

Developer of a synthetic peptide designed to provide treatment for benign tumors and various types of cancer. The company develops CyPep-1 peptide with a novel mechanism of action that guides the immune system to recognize and eradicate tumors, enabling patients to get treatment for cutaneous warts and malignant cancers.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Solheimsgaten 11
  • 5058 Bergen
  • Norway
+47 55
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Solheimsgaten 11
  • 5058 Bergen
  • Norway
+47 55

Cytovation Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytovation Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 23-Apr-2025 $6M Completed Clinical Trials - Phase 2
3. Later Stage VC (Series A) 02-Jun-2023 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series 1) 01-Jan-2019 $3.63M Completed Clinical Trials - Phase 1
1. Angel (individual) 08-Jan-2018 $3.63M $3.63M Completed Clinical Trials - Phase 1
To view Cytovation’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Cytovation Patents

Cytovation Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202413516-D0 Treatment of cancers associated with beta-catenin Inactive 13-Sep-2024
AU-2024351102-A1 Treatment of cancers associated with beta-catenin Pending 26-Sep-2023
EP-4784151-A1 Treatment of cancers associated with beta-catenin Pending 26-Sep-2023
GB-202314749-D0 Treatment of cancers associated with beta-catenin Inactive 26-Sep-2023
WO-2025068426-A1 Treatment of cancers associated with beta-catenin Inactive 26-Sep-2023 A61K38/1709
To view Cytovation’s complete patent history, request access »

Cytovation Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cytovation Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Additio Investment Group Venture Capital Minority
Canica PE/Buyout Minority
Sandwater Venture Capital Minority
To view Cytovation’s complete investors history, request access »

Cytovation FAQs

  • When was Cytovation founded?

    Cytovation was founded in 2001.

  • Where is Cytovation headquartered?

    Cytovation is headquartered in Bergen, Norway.

  • What is the size of Cytovation?

    Cytovation has 10 total employees.

  • What industry is Cytovation in?

    Cytovation’s primary industry is Drug Discovery.

  • Is Cytovation a private or public company?

    Cytovation is a Private company.

  • What is Cytovation’s current revenue?

    The current revenue for Cytovation is .

  • How much funding has Cytovation raised over time?

    Cytovation has raised $37.6M.

  • Who are Cytovation’s investors?

    Additio Investment Group, Canica, and Sandwater have invested in Cytovation.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process